What to know about CuATSM clinical trials

In this episode, Dr. Fernando Vieira, CSO at the ALS Therapy Development Institute (ALS TDI), joins us to discuss Copper ATSM (CuATSM)clinical trials. CuATSM is a small molecule drug sponsored by the company Collaborative MedicinalDevelopment (CMD). They recently completed enrollment of a small, Phase 1 clinical trial in Australia.

You can access all episodes of the Endpoints Podcast for free by visiting www.als.net/endpoints and registering.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.